[1] Boohaker RJ, Lee MW, Vishnubhotla P, et al. The use of therapeutic peptides to target and to kill cancer cells[J]. Curr Med Chem, 2012, 19(22):3794-3804. [2] Garcia M, Jemal A, Ward E, et al. Global cancer facts & figures[J]. American Cancer Society, 2013, 1(3):49-59. [3] Moxley KM, Mcmeekin DS. Endometrial carcinoma:a review of chemotherapy, drug resistance, and the search for new agents[J]. Oncologist, 2010, 15(10):1026-1033. [4] Clamp A, Jayson GC. The clinical development of the bryostatins [J]. Anticancer Drugs, 2002, 13(7):673-683. [5] Miguellillo B, Valenzuela B, Perisribera JE, et al. Population pharmacokinetics of kahalalide F in advanced cancer patients[J]. Cancer Chemotherapy & Pharmacology, 2015, 7(62):365-374. [6] Ratain MJ, Geary D, Undevia SD, et al. First-in-human, phase I study of elisidepsin(PM02734)administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors[J]. 2015, 33(4):901-910. [7] Sable R, Parajuli P, Jois S. Peptides, peptidomimetics, and polypeptides from marine sources:a wealth of natural sources for pharmaceutical applications[J]. Marine Drugs, 2017, 15(4):1-37. [8] Vaklavas C, Forero A. Management of metastatic breast cancer with second-generation antibody-drug conjugates:focus on glembatumumab vedotin(CDX-011, CR011-vcMMAE)[J]. BioDrugs, 2014, 28(3):253-263. [9] Van Andel L, Fudio S, Rosing H, et al. Pharmacokinetics and excretion of 14 C-Plitidepsin in patients with advanced cancer[J]. Investigational New Drugs, 2017. doi:10.1007/s10637-017-0425-5. [10] 陈巍, 严益民, 邓欣. 抗菌肽——一类新型抗肿瘤药物[J]. 海峡药学, 2014, 26(7):83-86. [11] 田彩平. 抗菌肽的分布及抗肿瘤作用[J]. 甘肃医药, 2011, 30(12):722-724. [12] Kao FS, Pan YR, Hsu RQ, et al. Efficacy verification and microscopic observations of an anticancer peptide, CB1a, on single lung cancer cell[J]. Biochimica Et Biophysica Acta, 2012, 1818(12):2927-2935. [13] Huang CY, Huang HY, Forrest MD, et al. Inhibition effect of a custom peptide on lung tumors[J]. PLoS One, 1932, 9(10):e109174. [14] 张城, 施丹, 刘卫清, 等. 心房利钠肽在心血管疾病中的研究进展[J]. 吉林医学, 2012, 33(4):820-822. [15] 李维玲, 吴敬波. 心房利钠肽原不同肽段的抗肿瘤机制[J]. 肿瘤预防与治疗, 2015(1):37-40. [16] 杨之, 陈宇, 李强等. 心钠肽、脑钠肽临床研究进展[J]. 吉林医学, 2010, 31(13):1912-1915. [17] 孙莎莎, 吕航吉, 文今福. 心房钠尿肽与心血管疾病关系的研究进展[J]. 泰山医学院学报, 2015(1):118-120. [18] Nojiri T, Hosoda H, Tokudome T, et al. Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells[J]. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(13):4086-4091. [19] 廖毅, 傅建伟, 陈英华. α1胸腺肽联合化疗治疗老年晚期胃癌临床效果及对外周血T淋巴细胞亚群影响研究[J]. 临床军医杂志, 2017(4):357-359. [20] Raghuraman H, Chattopadhyay A, Melittin:a membrane-active peptide with diverse functions[J]. Bioscience Reports, 2007, 27(4):189-223. [21] 高丽娇, 吴杰. 蜜蜂蜂毒主要成分与功能研究进展[J]. 基因组学与应用生物学, 2013, 32(2):246-253. [22] 陈伊凡, 胡福良. 蜂毒肽的抗癌作用及其机制[J]. 中国蜂业, 2014, 65:58-60. [23] 史怡雪, 李秦晋, 符文卉, 等. 蝎毒对Hela细胞p21基因表达的影响[J]. 经济动物学报, 2016, 20(3):163-167. [24] 金夕琳, 张洁, 江海龙, 等. 蛇毒毒素的抗肿瘤作用及其在医药领域的应用[J]. 药学实践杂志, 2015, 33(6):502-504, 517. [25] 李秀宁, 梁霞, 唐勇. 内皮抑素在膀胱癌中的研究进展[J]. 医学综述, 2016, 22(5):900-903. [26] 陈冠男, 余飞, 盛冠男, 等. 肿瘤血管生成拟态研究的希望与挑战[J]. 现代肿瘤医学, 2017, 25(1):138-141. [27] 张百红, 岳红云. 抗肿瘤靶向药物的分类[J]. 现代肿瘤医学, 2017, 25(2):299-303. [28] 卢筠, 谢强, 陈群, 等. 重组人血管内皮抑素联合顺铂胸腔内注射治疗肺腺癌恶性胸腔积液的临床研究[J]. 临床肺科杂志, 2016, 21(9):1664-1667. [29] 李有强, 王武峰, 彭少华. 血管内皮抑素联合同步放化疗治疗局部晚期下咽癌的效果评价[J]. 解放军医药杂志, 2016, 28(8):61-64. [30] Spadaro M, Curcio C, Varadhachary A, et al. Requirement for IFN-gamma, CD8 + T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu +tumors[J]. Cancer Res, 2007, 67(13):6425-6432. [31] Mader JS, Salsman J, Conrad DM, et al. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines[J]. Molecular Cancer Therapeutics, 2005, 4(4):612-624. [32] Wu JM, Jan PS, Yu HC, et al. Structure and function of a custom anticancer peptide, CB1a[J]. Peptides, 2009, 30(5):839-848. [33] Kao FS, Pan YR, Hsu RQ, et al. Efficacy verification and microscopic observations of an anticancer peptide, CB1a, on single lung cancer cell[J]. Biochimica Et Biophysica Acta, 2012, 1818(12):2927-2935. [34] Serafino A, Pierimarchi P. Atrial natriuretic peptide:A magic bullet for cancer therapy targeting Wnt signaling and cellular pH regulators[J]. Current Medicinal Chemistry, 2014, 21(21):2401-2409. [35] Shreyamshakumar BK, Patil CR. Characterization and functional expression of the natriuretic peptide system in human lens epithelial cells[J]. Molecular Vision, 2010, 16(72):630-638. [36] Jordan J, Grassi G. Natriuretic peptides in the cross-talk of human cardiovascular and metabolic regulation[J]. Journal of Hypertension, 2015, 33(6):1139-1141. [37] Wolf JS, Guoyan L, Atul V. et al. Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2007, 13(5):1601-1610. [38] 李睿, 吴宗好, 陈卫东. 小分子多肽的来源新进展[J]. 中南药学, 2016, 14(2):175-178. [39] 赵锐, 孟庆义, 邓欣, 等. 多肽抗肿瘤化合物的研究进展[J]. 海峡药学, 2012, 24(10):4-8. [40] 康丽花, 欧阳晓晖, 苏秀兰. 生物活性肽的抗癌作用及其作用机制研究进展[J]. 内蒙古医科大学学报, 2015(4):383-387. |